Volibo (Voglibose) 0.3mg – 100 tablet

USD $59.20

Each Volibo contains .3mg Voglibose 100 tablets and is used to lower blood glucose level in patients with Type 2 Diabetes Mellitus

ATC Classification: A10BF03
Active Ingrediant: Voglibose
Generic Name: Volibo
Manufacturer: Sun Pharma
Strength: 0.3mg
Dosage Type: Tablet
Packaging Type: Foil in Box
Contains: 100 TABLET

Examples of Packages sent

 

Product Availability (US)

Not available in US

 

Storage/Stability

Store at room temperature. Protect from moisture.

 

Adverse Reactions

Frequency not always defined.

Cardiovascular: Facial edema (<5%)

Central nervous system: Burning sensation (<5%), malaise (<5%), numbness (<5%)

Dermatologic: Alopecia (<5%)

Endocrine & metabolic: Changes in LDH (<5%, increased), decreased HDL cholesterol (<5%), hyperkalemia (<5%), increased alpha-1-antitrypsin (<5%), increased gamma-glutamyl transferase (<5%), hyperammonemia

Gastrointestinal: Abdominal distention (<5%), abdominal pain (<5%), anorexia (<5%), constipation (<5%), diarrhea (<5%), dyspepsia (<5%), flatulence (<5%), heartburn (<5%), increased serum amylase (<5%), loose stools (<5%), nausea (<5%), vomiting (<5%), intestinal obstruction

Hematologic & oncologic: Anemia (<5%)

Hepatic: Increased serum ALT (<5%), increased serum AST (<5%), hepatitis (acute)

Neuromuscular & skeletal: Weakness (<5%)

Ophthalmic: Decreased visual acuity (<5%)

Miscellaneous: Fever (<5%)

<1%, postmarketing, and/or case reports: Delayed gastric emptying, dizziness, drowsiness, dysgeusia, gastritis, headache, hypoglycemia, jaundice, photophobia, pneumatosis cystoides intestinalis, polydipsia, pruritus, severe hepatic insufficiency, skin rash, staggering, stomatitis, thrombocytopenia, tongue ulcer

Additional information

Active Ingrediant

Generic Name

Alternate Names

, , , , , , , , , ,

Strength

Dosage Type

Packaging Type

Brand

Sun Pharma

Reviews

There are no reviews yet

Be the first to review “Volibo (Voglibose) 0.3mg – 100 tablet”

Your email address will not be published. Required fields are marked *